AN2 Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that AN2 Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($9.35M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($6.46M) | Aug 12, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($6.46M) | Nov 12, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($10.65M) | Nov 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($10.65M) | May 13, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($10.65M) | Aug 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($12.75M) | Nov 12, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($14.44M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($14.44M) | Aug 12, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($16.62M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($16.62M) | May 13, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($16.62M) | Nov 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($16.71M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($15.80M) | Aug 13, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($15.80M) | Nov 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($15.32M) | May 14, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($15.32M) | Nov 13, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($15.32M) | Aug 13, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($11.34M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($10.12M) | Aug 10, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($10.04M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($7.22M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($11.54M) | May 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($14.01M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($15.88M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($18.30M) | May 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($18.18M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($16.60M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($16.04M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($11.77M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($10.33M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($7.68M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($6.93M) | Nov 9, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($5.00M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($2.05M) | May 10, 2022 |